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Abstract
Introduction: Kaposi sarcoma (KS) is the leading cause of cancer in Uganda and occurs in people with and without HIV.
Human herpesvirus-8 (HHV-8) replication is important both in transmission of HHV-8 and progression to KS. We
characterized the sites and frequency of HHV-8 detection in Ugandans with and without HIV and KS.
Methods: Participants were enrolled into one of four groups on the basis of HIV and KS status (HIV negative/KS negative,
HIV positive/KS negative, HIV negative/KS positive, and HIV positive/KS positive). Participants collected oral swabs daily and
clinicians collected oral swabs, anogenital swabs, and plasma samples weekly over 4 weeks. HHV-8 DNA at each site was
quantified by polymerase chain reaction (PCR).
Results: 78 participants collected a total of 2063 orals swabs and 358 plasma samples. Of these, 428 (21%) oral swabs and 96
(27%) plasma samples had detectable HHV-8 DNA. HHV-8 was detected more frequently in both the oropharynx of persons
with KS (24 (57%) of 42 persons with KS vs. 8 (22%) of 36 persons without, p=0.002) and the peripheral blood (30 (71%) of 42
persons with KS vs. 8 (22%) of 36 persons without, p,0.001). In a multivariate model, HHV-8 viremia was more frequent among
men(IRR=3.3,95%CI=1.7–6.2,p,0.001),personswithKS(IRR=3.9,95%CI=1.7–9.0,p=0.001)andpersonswithHIVinfection
(IRR=1.7,95% CI=1.0–2.7,p=0.03).Importantly,oralHHV-8detectionpredictedthesubsequentHHV-8viremia.HHV-8viremia
was significantly more common when HHV-8 DNA was detected from the oropharynx during the week prior than when oral
HHV-8 was not detected (RR=3.3, 95% CI=1.8–5.9 p,0.001). Genital HHV-8 detection was rare (9 (3%) of 272 swabs).
Conclusions: HHV-8 detection is frequent in the oropharynx and peripheral blood of Ugandans with endemic and epidemic KS.
Replication at these sites is highly correlated, and viremia is increased in men and those with HIV. The high incidence of HHV-8
replication at multiple anatomic sites may be an important factor leading to and sustaining the high prevalence of KS in Uganda.
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Introduction
African (‘‘endemic’’) Kaposi sarcoma (KS) was originally
described in Uganda in the 1960s [1]. Today, KS is one of the
leading causes of cancer in Uganda, in children and adults of both
genders [2], largely attributable to the dramatic increase in KS
incidence in persons with HIV infection [3]. HIV associated
(‘‘epidemic’’) KS has very high morbidity and mortality and has
become a significant health problem in this region [4].
Human herpesvirus-8 (HHV-8) is the causative agent of all
forms of KS [5,6], and infection is endemic in Uganda, with an
estimated seroprevalence between 36% and 60% [7,8,9,10].
Despite this high seroprevalence, both endemic and epidemic
KS occur in a minority of persons who are HHV-8 infected, and
little is known about the underlying mechanisms determining the
transition from asymptomatic HHV-8 infection to KS disease.
Specifically, what role the site, persistence, and quantity of HHV-8
replication play in progression to KS is unclear. HHV-8
PLoS ONE | www.plosone.org 1 January 2009 | Volume 4 | Issue 1 | e4222replication patterns, as measured by detection of viral DNA from
samples collected from mucosal surfaces, have been defined in
several longitudinal and cross sectional studies, with virus
predominantly detected from the oral mucosa [11,12,13]. For
example, a study of HHV-8 infected men in the US demonstrated
HHV-8 by polymerase chain reaction (PCR) from 30% of oral
swabs, 15% plasma and PBMC samples, and ,1% of anogenital
secretions [11]. Oral epithelial cells had detectable HHV-8 mRNA
and DNA [11], and HHV-8 DNA in saliva was protected from
digestion with DNase, consistent with the presence of virions [14].
Lytic HHV-8 replication in the vascular compartment is
thought to play an essential role in the pathophysiology of
epidemic KS [15]. Cross sectional studies of HHV-8 plasma
viremia in patients with epidemic KS have shown an association
with KS stage [16] and KS progression, but not KS burden [17].
The role of HHV-8 replication in non-epidemic forms of KS is less
clear. HHV-8 viremia was not significantly associated with KS
stage in classic KS [18], and HHV-8 viremia in persons with
endemic KS has not been comprehensively studied. Whether loss
of control of HHV-8 replication occurs in the oral compartment
and precedes, occurs in conjunction with, or is independent of the
development of KS is not known.
To gain insight into the pathophysiology of HHV-8 replication
in association with endemic and epidemic KS in Uganda, we
conducted a prospective cohort study using detailed sampling
methods among HIV-infected and HIV-uninfected persons with
or without KS to describe the sites and patterns of HHV-8
mucosal and plasma replication in a region where both HHV-8
and KS are highly prevalent.
Results
Study participants
Eighty-seven participants were enrolled in the study: one
participant did not have histological confirmation of KS, and
another participant enrolled but was lost to follow up before
collecting any oral swabs: these participants were excluded from
further analyses (Figure 1). Eighty-three (98%) of 85 participants
had serum available for HHV-8 antibody testing, and of these 70
(84%) were HHV-8 seropositive. The two participants without
serum available had biopsy-proven KS and therefore had evidence
of HHV-8 infection. Similarly, 6 (46%) of 13 HHV-8 seronegative
persons had clinical or virologic evidence of HHV-8 infection and
hence had false negative HHV-8 serologies (3 persons had HHV-8
detected from $1 mucosal samples and biopsy proven KS, 1 had
biopsy proven KS only, 2 had HHV-8 detected from mucosal
samples on $1 occasion); these participants were therefore
included in the analyses. Seven (54%) of 13 HHV-8 seronegative
participants who did not have clinical or laboratory evidence of
HHV-8 infection were excluded from further analyses.
The remaining cohort consisted of 78 participants who were
distributed across four groups: 17 HIV negative/KS negative, 19
HIV positive/KS negative, 20 HIV negative/KS positive and 22
HIV positive/KS positive (Table 1). Eighteen (50%) of 36
participants without KS were women, compared with 10 (24%)
of 42 participants with KS (p=0.02). The median age was 32
(range 18–60) and did not differ across the groups (p=0.50).
There was no significant difference in proportion of members of
the Baganda tribe (the most populous tribe in Kampala), in those
with and without KS (p=0.51). Among HIV-infected persons
with and without KS, there was no difference in the median
CD4+ T-cell count (p=0.08), or median HIV plasma RNA level
(p=0.13). Among participants with KS, persons with HIV were
more likely to have advanced disease, with presence of edema
and/or visceral disease, including oral involvement [19] (p=0.01).
There were no differences between tobacco use (p=0.06) or
alcohol consumption (p=0.88) in participants with and without
KS. People with KS had a slightly later sexual debut compared to
those without KS (19 years old vs. 18 years old, p=0.03).
Condom use was rare in all groups; HIV-infected persons had
significantly more lifetime sexual partners compared to HIV-
seronegative persons (p,0.001).
Figure 1. Enrollment and follow-up of participants in HHV-8 replication study.
doi:10.1371/journal.pone.0004222.g001
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Overall, 2969 (89%) of 3354 expected samples were collected
and available for analysis, and subjects attended 377 (97%) of 390
protocol visits. From the 78 subjects, a total of 2063 oral swabs
were collected on a median of 29 days per person and of these, 428
(21%) had HHV-8 DNA detected by PCR. The quantity of HHV-
8 detected in oral swabs was highly correlated between
participant-collected and clinician-collected oral swabs (Spearman
correlation coefficient=0.87, Figure 2). Among those oral swabs
positive for HHV-8 DNA, the amount of HHV-8 detected from
participant collected swabs was 0.9 log copies/ml higher than that
detected from clinician collected swabs (p,0.001).
Thirty-two (41%) participants had HHV-8 DNA detected from
oral swabs (‘‘shedding’’) on $1 day. The proportion of participants
with oral HHV-8 shedding was significantly higher in persons with
KS as compared to those without KS (p=0.002). Three (18%)
HIV negative/KS negative persons and 5 (26%) HIV positive/KS
negative persons had HHV-8 DNA detected from the oral
mucosa. In contrast, 10 (50%) HIV negative/KS positive and 14
(64%) HIV positive/KS positive persons had oral HHV-8
shedding (Figure 3, Table 2). The median per person oral
HHV-8 detection rate was highest in the persons with epidemic
KS (27% of days), but was not significantly different in those with
and without KS (p=0.10) (Table 2). The median amount of
HHV-8 detected from oral swabs was significantly lower in HIV
positive/KS positive persons (3.9 log copies/ml), as compared to
other groups (5.5 log copies/ml, p=0.004).
Three hundred fifty eight plasma samples were collected from
the 78 participants (median of 5 separate samples per participant).
Of these, 96 (27%) were positive for HHV-8 DNA. Thirty-eight
(49%) participants had HHV-8 detectable in $1 plasma sample
(Figure 3, Table 2). The proportion of participants with HHV-8
detected in plasma was significantly higher in persons with KS, as
compared to those without KS (p,0.001). Among KS negative
persons, 4 (22%) of 17 HIV-infected and 4 (21%) of 19 HIV-
uninfected persons had detectable HHV-8 in the blood. Thirteen
(65%) of 20 people with endemic KS and 17 (77%) of 22 people
with epidemic KS had HHV-8 viremia. The median rate per
person of HHV-8 viremia was 0% in persons without KS, 20% in
persons with endemic KS, and 67% in persons with epidemic KS
(p,0.001 for KS negative vs. KS positive). The median amount of
HHV-8 DNA detected in plasma was significantly greater in
participants with HIV (3.3 log copies/ml), as compared to those
without HIV (2.8 log copies/ml), regardless of KS status
(p=0.007).
Of the 272 swabs collected from the genital tract, only 9 (3%)
were positive for HHV-8 DNA and 5 (56%) of 9 came from one
study subject who had genital KS. The median per person
shedding rate and amount of genital HHV-8 DNA detected did
not differ in KS positive and KS negative persons.
Individual rates of HHV-8 detection, by HIV and KS status
Individual patterns of HHV-8 oral shedding differed by HIV and
KS status. Interestingly, we identified several KS negative subjects
whoshed HHV-8fromtheiroropharynxathighfrequency.HHV-8
wasshed from theoralmucosa ongreaterthan 70% ofdaysin2 of 3
HIV negative/KS negative and 3 of 5 HIV positive/KS negative
participants who had oral HHV-8 detection (Figure 4). Six (60%) of
10 endemic KS participants with oral HHV-8 detected also shed
HHV-8 from the mouth on greater than 70% of days. The other
participants in these 3 groups exhibited low rates of oral HHV-8
detection (,30% of the days sampled). The pattern of HHV-8 oral
detection was not dichotomous in epidemic KS, with 4 (29%) of 14
participants shedding on over 70% of days sampled, 7 (50%)
participants shedding between 30% and 70% of days, and 3 (21%)
shedding ,30% of days.
Table 1. Demographic, clinical and behavioral characteristics of participants.
HIV2/KS2 HIV+/KS2 HIV2/KS+ HIV+/KS+
N=17 N=19 N=20 N=22
Female 11 (65) 7 (37) 5 (25) 5 (23)
Median age (range) 34 (22–58) 32 (23–50) 32 (18–60) 35 (19–48)
Member of Baganda tribe 11 (65) 8(42) 6 (30) 13 (59)
Median CD4 count (number/mm
3) (range)
A - 475 (309–829) - 391 (208–1062)
HIV plasma RNA level, Log10 copies/ml (median, range)
A 4.5 (2.3–5.6) 4.8 (2.3–5.9)
HHV-8 seropositive by IFA
B 16 (94) 18 (95) 15 (75) 21 (96)
Advanced KS
C, * - - 6(30) 15 (68)
Consume at least 2 alcoholic beverages per week 4 (24) 6 (32) 3 (15) 8 (36)
Smoker 3 (18) 6 (32) - 4 (18)
Always uses condom with sexual activity
D 1 (6) 6 (32) 6 (30) 3 (14)
Median age at 1
st vaginal sex (range) 18 (12–25) 17 (8–25) 19 (11–28) 18 (15–25)
Median number of vaginal sex partners in past yr (range) 1 (0–2) 1 (0–5) 1 (0–4) 1 (0–20)
Median number of vaginal sex partners in lifetime (range) * 2 (1–7) 7 (1–80) 3 (0–15) 6 (2–50)
All values are n (%) unless otherwise indicated.
Rows in bold indicate p-value,0.05, for comparison between KS positive and KS negative persons, unless otherwise stated. P-values were calculated using chi-square,
Fisher’s exact, or Kruskal-Wallis tests, when appropriate.
*p-value,0.05 for comparison between HIV positive and HIV negative persons, calculated using chi-square or Kruskal-Wallis test.
AMeasured for HIV positive participants only.
BData missing for 2 participants (1 HIV negative/KS positive, 1 HIV positive/KS positive).
COnly KS positive participants (n=42) included in denominator.
DData missing for 2 participants.
doi:10.1371/journal.pone.0004222.t001
HHV-8 Replication in Uganda
PLoS ONE | www.plosone.org 3 January 2009 | Volume 4 | Issue 1 | e4222In KS negative persons, HHV-8 viremia was more sporadic,
present on less than 30% of days in 3 of 4 HIV negative/KS
negative and 2 of 4 HIV positive/KS negative participants who
had HHV-8 detected in the blood. Five (39%) of 13 participants
with endemic KS were viremic on less than 30% of days, and two
(15%) of 13 had HHV-8 viremia on 100% of days sampled. In
contrast, ten (82%) of 17 participants with epidemic KS were
viremic on greater than 70% of the days sampled, and 6 (35%) of
these were viremic on 100% of days sampled.
We examined the association between HHV-8 oral shedding
and viremia on a per person basis, and found that oral HHV-8
DNA predicted the detection of HHV-8 in the blood. HHV-8 was
detected significantly more often from plasma samples collected
when HHV-8 was shed from the oropharynx during the week
prior than during periods when HHV-8 was not shed from the
oropharynx (RR=3.3, 95% CI=1.8–5.9, p,0.001). Overall, 31
(62%) of 50 days with HHV-8 detected in plasma had HHV-8 oral
shedding on at least one day during the prior week. Conversely,
Figure 2. Correlation between HHV-8 detection in participant- and clinician- collected oral swabs. The quantity of HHV-8 DNA detected
in oral swabs collected at home by participants was compared to those collected in clinic by trained clinicians. R=Spearman correlation coefficient.
doi:10.1371/journal.pone.0004222.g002
Figure 3. Proportion of participants with HHV-8 detected, by anatomic site and HIV and KS status. Percentage of participants with HHV-
8 detected from oral swabs, genital swabs, or plasma samples. Participants collected a median of 29 oral swabs, 4 genital swabs, and 5 plasma
samples. *p,0.05 for the comparison of the proportion of KS positive to KS negative participants with detectable HHV-8, using chi-square test.
doi:10.1371/journal.pone.0004222.g003
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following week (RR=1.7, 95% CI=0.8–3.6, p=0.14).
Correlates of HHV-8 oral shedding and viremia
Correlates of HHV-8 detection in the oral mucosa were
determined by univariate and multivariate modeling (Table 3). In
the univariate analysis, men had an increased risk of oral HHV-8
shedding (IRR=3.1, 95% CI=1.0–9.3, p=0.05) and participants
with KS trended toward an increased risk of oral shedding
(IRR=2.1, 95% CI=0.9–5.0, p=0.10). HIV infection did not
increase the likelihood of oral shedding (IRR=1.0, 95% CI=0.5–
2.2, p=0.98), and HIV RNA level and CD4+ T-cell count were
not associated with oral HHV-8 detection. In multivariate models,
KS status and male sex remained associated with increased oral
HHV-8 detection, but the association was no longer statistically
significant. Having more than one sexual partner in the past year
was associated with 3.4 fold increase in HHV-8 oral shedding rate
(IRR=3.4, 95% CI=1.1–10.2, p=0.03), while consistent con-
dom use (IRR=0.3, 95% CI=0.1–0.9, p=0.03), alcohol use
(IRR=0.4, 95% CI=0.2–0.9, p=0.02), and younger age (,=15
years) at sexual debut (IRR=0.2, 05% CI=0.03–0.8, p=0.02)
were associated with a significantly reduced risk of oral HHV-8
detection (Table 3).
In univariate analyses, correlates of HHV-8 plasma viremia
included male sex (IRR=4.5, 95% CI=2.0–10.1, p,0.001), HIV
infection (IRR=1.9, 95% CI=1.0–3.4, p=0.04), plasma HIV
RNA level above 4.5 log (IRR=1.6, 95% CI=1.1–2.3, p=0.02)
and having KS (IRR=5.4, 95% CI=2.3–12.5, p,0.001). In
multivariate models, male sex, HIV infection, and KS status
remained significantly associated with HHV-8 viremia. In
addition, being a member of the Baganda tribe was associated
with HHV-8 viremia (IRR=1.9, 95% CI=1.2–3.1, p=0.006)
and having more than one sex partner during the past year was
associated with a reduced risk of viremia (IRR=0.6, 95%
CI=0.4–0.9, p=0.01). A sensitivity analysis, which included
those participants without laboratory evidence of HHV-8 infection
by either HHV-8 seropositivity, HHV-8 DNA detection from
mucosal surfaces or blood, or biopsy proven KS, did not change
the results of multivariate models for oral HHV-8 detection or
viremia (data not shown).
Discussion
We conducted a comprehensive study of the natural history of
HHV-8 infection in an area where HHV-8 infection and KS are
endemic and demonstrated; 1) HHV-8 DNA detection in the
oropharynx and peripheral blood is common and highly
correlated; 2) individual patterns of oral and plasma HHV-8
replication differ in persons with and without endemic and
epidemic KS; and 3) HHV-8 viremia is more frequent among men
and among persons with KS or HIV-infection.
While daily home collection of mucosal samples for herpesvirus
culture and PCR has been validated in multiple studies in
resource-rich settings, [11,12,20,21,22,23], to our knowledge this
is the first study to perform intensive mucosal sampling in a
resource-limited setting. Our finding that the frequency of
detection of HHV-8 DNA in oral swabs collected by the
participant was highly correlated with that of clinician-collected
swabs is an important operational research concept, for it
demonstrates the feasibility of characterizing home-collected
samples for DNA testing for infectious agents in field settings in
resource-limited areas. Similar to results from shedding studies
performed in the United States, participant collected swabs had
significantly higher copy number of virus than clinician collected
swabs [20], perhaps reflecting that once instructed on methods for
sampling mucosal surfaces, self-obtained samples appear to be
collected more consistently and vigorously than clinician-obtained
samples.
We found that oral HHV-8 detection was associated with
multiple recent sex partners, and that remote sexual debut and
consistent condom use with sexual activity were associated with
reduced risk of oral HHV-8 shedding. These results are consistent
Table 2. Frequency and Quantity of HHV-8 Detection among Participants with and without HIV and KS.
Oral Swabs HIV2/KS2 HIV+/KS2 HIV2/KS+ HIV+/KS+ P value
N=17 N=19 N=20 N=22
Persons with HHV8 detected on $1 day, n (%) 3 (18) 5 (26) 10 (50) 14 (64) 0.002
a
Per person HHV-8 detection rate, median (range) 0 (0–96%) 0 (0–100%) 2% (0–100%) 27% (0–100%) 0.10
b
HHV-8 DNA log10 copies/mL*, median (range) 5.3 (2.7–6.9) 5.2 (2.8–7.3) 5.6 (2.3–7.8) 3.9 (2.7–6.1) 0.004
c
Plasma
Persons with HHV8 detected on $1 day, n (%)
e 4 (24) 4 (21) 13 (65) 17 (77) ,0.001
a
Per person HHV-8 detection rate, median (range) 0 (0–40%) 0 (0–100%) 20% (0–100%) 67% (0–100%) ,0.001
b
HHV-8 DNA log10 copies/mL*, median (range) 2.6 (2.0–3.2) 3.3 (2.8–4.4) 2.9 (1.8–4.5) 3.4 (2.0–4.6) 0.007
d
Genital Swabs
Persons with HHV8 detected on $1 day, n (%) 0 1 (5) 1 (5) 3 (14) 0.36
a
Per person HHV-8 detection rate, median (range)
f 0 (0–0) 0 (0–25%) 0 (0–33%) 0 (0–100%) 0.09
b
HHV-8 DNA log10 copies/mL*, median (range) - 3.2
g 4.2
g 3.7 (3.2–4.6) 0.22
c
*Among positive samples.
aP-value refers to comparison between KS negative and KS positive persons, using chi-square test.
bP-value refers to comparison between KS negative and KS positive persons, using GEE Poisson regression.
cP-value refers to comparison between HIV+/KS+ persons compared to the other groups, using GEE Gaussian regression.
dP-value refers to comparison between HIV positive and HIV negative persons, using GEE Poisson regression.
eMissing for 1 HIV+/KS+ participant.
fMissing for 2 HIV+/KS+,2K S +/HIV2,a n d1K S 2/HIV2 participants.
gOnly 1 positive swab collected.
doi:10.1371/journal.pone.0004222.t002
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described in a cohort of Kenyan men [24]. HHV-8 transmission in
adults in this population could be through similar saliva sharing
practices that put children at risk [25,26], or it could be through
other behavioral practices associated with high risk sexual activity,
as seen with deep kissing in men who have sex with men (MSM) in
the United States (US) [11,27]. Elucidation of specific behaviors
that are associated with transmission and oral replication of HHV-
8 among Ugandan adults will require further study. Consistent
with prior studies of HHV-8 replication patterns [11,12,28],
HHV-8 was rarely detected from the genital mucosa in Ugandan
men or women, particularly in the absence of KS.
HHV-8 viremia occurred frequently among persons with both
epidemic KS and endemic KS. In addition, HHV-8 viremia
appeared sustained throughout the 28 day study period in nearly
30% of persons with KS. While sustained and frequent viremia
has been reported in patients with epidemic KS, our data in
endemic KS provide further evidence that disseminated and
persistent viral replication may be important to the pathophysi-
ology of development of KS, independent of HIV status.
Our finding that HHV-8 viremia was associated with a greater
than 3-fold increased risk of HHV-8 oral detection during the
prior week suggests that a loss of control of HHV-8 replication in
the mucosal compartments may contribute to the development of
viremia and progression of KS. Our data are consistent with a
model that lytic HHV-8 replication in the oral compartment
precedes HHV-8 viremia, and that HHV-8 dissemination to the
vascular compartment is necessary for development of KS. The
high frequency of HHV-8 viremia in epidemic KS may also be a
factor in sustaining and seeding areas of established KS [29],
making eradication and therapy more difficult. These data
indicate that understanding factors associated with HHV-8
replication in the mucosal compartment is important for
understanding KS pathogenesis.
The observation of a dichotomous oral replication pattern in
Ugandans with asymptomatic HHV-8 infection, between those
with frequent and high quantity detection or infrequent and low
quantity detection, is similar to results seen in a US based
population of asymptomatic HHV-8 infected MSM [11,12].
These data in combination with our observations that more
frequent viremia is seen in men, especially members of the
Baganda tribe, are intriguing aspects of the pathophysiology of KS
in Uganda. Whether there are specific behavioral, environmental,
or genetic cofactors that account for these observations is unclear.
Familial clusters of classic KS have been described, without
identified genetic predisposition [30,31]. In French Guyana, the
pattern of HHV-8 seropositivity was consistent with the presence
of a major recessive gene predisposing to HHV-8 infection [32].
Figure 4. Rate of HHV-8 detection from oral swabs and plasma samples in individual participants, by HIV and KS status. Participants
are numbered in ascending order according to oral shedding rate in each group. The participants collected a median of 29 oral swabs, 4 genital
swabs, and 5 plasma samples per person.
doi:10.1371/journal.pone.0004222.g004
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production were associated with KS development in HIV-infected
men [33].
We were surprised that HIV infection did not have a more
profound influence on HHV-8 oral replication and viremia in our
cohort. In previous studies of women in Kenya, HIV seropositivity
was associated with a 2-fold increased risk of HHV-8 detection
from any mucosal surface [13]. In this study, HIV status, CD4+ T-
cell count, and HIV plasma RNA level were not associated with
oral HHV-8 detection. However, HHV-8 viremia was associated
with HIV seropositivity in both univariate and multivariate
analyses. It is possible that an association between HIV infection,
HIV plasma RNA levels and HHV-8 oral shedding exists, but that
our sample size was too small to detect it. Alternatively, our
inclusion of only HIV-positive participants with CD4+ T-cell
counts greater than 200/mm
3 may have led to an underestimation
of the relationship between HIV and HHV-8 replication, though
previous work from our group and others has shown HHV-8 oral
replication to be more common in HIV-positive persons with
higher CD4+ T-cell counts [23,34]. Interestingly, we found that
despite more frequent HHV-8 detection in the oropharynx of
persons with epidemic KS, the quantity of HHV-8 detected was
lower compared with other groups. This has not been described in
the only other study that compared HHV-8 oral replication
patterns among HIV-infected persons with or without KS [35].
Careful studies of the biology of HHV-8 oropharyngeal replication
may clarify the factors governing the frequency and quantity of
HHV-8 oral shedding in saliva.
This study is limited by a short follow up period. Longer
prospective studies of HIV-infected persons with high rates of oral
HHV-8 detection and viremia are ongoing to determine if
sustained HHV-8 replication is associated with the development
of KS. If HHV-8 viremia does precede KS, as suggested by other
cohorts [15,16,17], prevention of KS in HHV-8 viremic high risk
populations with the use of antiviral agents with activity against
HHV-8, such as valganciclovir [36],, would be of interest for
further study.
In summary, we demonstrate that intensive virologic studies can
be carried out in resource limited settings, and that lytic replication
of HHV-8 in both the oral and vascular compartments is highly
associated with the presence of endemic as well as epidemic KS.
Detection of HHV-8 in these compartments is highly correlated,
suggesting that mucosal HHV-8 replication may be an important
antecedent of HHV-8 viremia. Understanding the cofactors that
influence HHV-8 acquisition, reactivation and persistence is likely
to lead to novel strategies to reduce HHV-8 associated KS.
Methods
Participants, Setting and Study Design
The study was conducted at the Uganda Cancer Institute (UCI),
Mulago Hospital, Makerere University, Kampala, Uganda
between May 2005 and July 2006. Participants between the ages
of 18 and 65 were recruited from the UCI, the Infectious Disease
Institute (IDI) and through word of mouth. Eighty-seven
participants were enrolled into one of four groups on the basis
of HIV and KS status: HIV negative/KS negative, HIV positive/
KS negative, HIV negative/KS positive and HIV positive/KS
positive. Participants unable to give written or verbal informed
consent or taking acyclovir or ganciclovir were ineligible for the
study. In addition, HIV positive participants who had a CD4+ T-
cell count less than 200/mm
3 or were taking antiretroviral
medication (ARV) were ineligible. All participants gave informed
consent for study participation and, when performed, HIV testing.
Verbal consent was obtained in place of written consent if
participants were unable to read and understand the consent form.
Ethical approval for all study procedures, including verbal and
written informed consenting procedures, was obtained from the
Makerere University Research and Ethics Committee, the Uganda
National Council for Science and Technology, and the University
of Washington Human Subjects Division.
Table 3. Univariate and multivariate analyses of factors associated with HHV-8 oral shedding and viremia.
BIOLOGIC FACTORS HHV-8 Oral Shedding HHV-8 Viremia
Unadjusted Adjusted Unadjusted Adjusted
IRR (95% CI) P value IRR (95% CI)
B P value IRR (95% CI) P value IRR (95% CI)
B P value
Age 1.0 (1.0–1.0) 0.61 – 1.0 (1.0–1.0) 0.96 –
Men (vs. women) 3.1 (1.0–9.3) 0.05 2.1 (0.6–7.4) 0.23 4.5 (2.0–10.1) ,0.001 3.3 (1.7–6.2) ,0.001
HIV seropositive 1.0 (0.5–2.2) 0.98 1.0 (0.5–2.0) 0.98 1.9 (1.0–3.4) 0.04 1.7 (1.0–2.7) 0.03
CD4 count
A 1.0 (1.0–1.0) 0.71 – 1.0 (1.0–1.0) 0.62 –
HIV plasma RNA level.4.5 log (vs.,4.5)
A 1.2 (0.7–2.1) 0.62 – 1.6 (1.1–2.3) 0.02 –
KS present 2.1 (0.9–5.0) 0.1 1.3 (0.6–2.8) 0.47 5.4 (2.3–12.5) ,0.001 3.9 (1.7–9.0) 0.001
Baganda tribe (vs. other tribes) 1.0 (0.5–2.1) 0.97 – 1.7 (0.9–3.1) 0.09 1.9 (1.2–3.1) 0.006
BEHAVIORAL FACTORS
Alcohol use (vs. no alcohol use) 0.6 (0.3–1.4) 0.24 0.4 (0.2–0.9) 0.02 0.7 (0.4–1.4) 0.31 –
$1 sexual partner during past year (vs. no
sex partners)
2.4 (0.9–6.8) 0.09 3.4 (1.1–10.2) 0.03 0.8 (0.4–1.4) 0.37 0.6 (0.4–0.9) 0.01
#15 years of age at sexual debut (vs..15 years) 0.1 (0.03–0.4) 0.001 0.2 (0.03–0.8) 0.02 0.5 (0.2–1.2) 0.14 –
100% condom use (vs.,100% use)
C 0.4 (0.1–1.5) 0.17 0.3 (0.1–0.9) 0.03 0.7 (0.3–1.6) 0.42 –
Abbreviations: IRR=incidence rate ratio, CI=confidence interval, vs=versus.
ACalculated for HIV seropositive participants only.
BMultivariate model, adjusted for other variables indicated in table.
CData missing for 2 participants.
doi:10.1371/journal.pone.0004222.t003
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At the screening visit, a questionnaire which collected
information about demographic, sexual, and behavioral practices
was administered. At enrollment, past medical history, current
symptoms and medications were obtained, and a physical
examination was performed, including detailed documentation
of location and size of KS lesions. All participants with KS had
histologically-confirmed disease. Participants were taught oral
swab collection techniques, which included vigorously swabbing
the buccal mucosa, gums, tongue, hard palate and tonsils with a
Dacron swab. The swab was placed in a vial containing 1 ml of
filter sterilized 16 digestion buffer [37] and stored at room
temperature. Participants collected daily swabs of the oral mucosa
at home for 28 days. Swabs were returned at weekly clinical visits,
where a focused physical exam was performed and oral and
anogenital swabs and plasma samples were obtained by a clinician.
All samples were collected in duplicate. Samples were processed
and stored at the Makerere University-Johns Hopkins University
(MUJHU) laboratory at 280uC. One set of samples was shipped
to the University of Washington for HHV-8 PCR testing and
HHV-8 serology.
Laboratory Testing
For those who could not provide written documentation of HIV
test results within the past 6 months, HIV serostatus was ascertained
using the Determine HIV K lateral flow qualitative rapid
immunoassay on whole blood (Inverness Medical Innovations
Inc.) Positive results were confirmed with the Clearview Stat-Pak
(Inverness Medical Innovations Inc). CD4+ T-cell count was
determined in HIV-positive persons at the MUJHU laboratory
using standard cell sorting techniques. HHV-8 serostatus was
determined at the University of Washington, using an immunoflu-
orescence assay (IFA) to detect serum antibodies to latent and lytic
proteins as previously described [38], with the presence of either
considered serologic evidence of HHV-8 infection. DNA was
extracted from mucosal swabs and plasma [12] and HHV-8 DNA
was measured quantitatively with a real-time fluorescent polymer-
ase chain reaction (PCR) with primers to the orf73 gene, with
positive and negative controls as previously described [11,12].
Mucosal samples with $150 copies and plasma samples with $50
copies HHV-8 DNA/ml were considered positive for HHV-8 [39].
Statistical Analysis
Chi-square tests or non-parametric Kruskal-Wallis (KW) tests
were used to assess the homogeneity of demographic and virologic
characteristics according to KS and HIV status. Quantity of
HHV-8 DNA (copies/ml) was log10 transformed for analysis.
Detection of HHV-8 in participant- and clinician-collected oral
samples was evaluated with a Spearman-rank correlation coeffi-
cient. Oral shedding rates were calculated using participant-
collected daily oral swabs only, unless such swabs were unavailable
on clinic visit days, in which case the results from clinician-
collected oral swabs were used. Summary shedding rates for oral,
anogenital and plasma samples were calculated per participant
(persons with at least one sample with HHV-8 detected/total
participants) and per sample (swabs or plasma samples with HHV-
8 DNA detected/total samples collected).
All regression models used generalized estimating equations
(GEE) with an exchangeable correlation structure to adjust for
intra-individual correlation of repeated measures per person, and
the Huber-White variance estimator. Two sided p-values#0.05
were considered statistically significant.
The difference in HHV-8 DNA copy number among clinician-
and participant-collected oral swabs and among groups was
determined using GEE Gaussian regression with an identity link.
Correlates of HHV-8 oral mucosal and plasma detection were
identified via univariate and multivariate GEE Poisson regression.
All covariates that were associated with HHV-8 detection at the
p,0.1 and p,0.2 levels in univariate analyses were assessed as
significant predictors or confounders of HHV-8 detection.
Confounders were retained if they changed the beta coefficients
of predictors by greater than 10%. The association between HHV-
8 viremia and oral HHV-8 detection was assessed using GEE
binomial regression with a log link. Statistical analyses were
performed using Stata, version 10.0.
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